[{"id":"9259cd2b-7d10-4e29-a71a-448de9ccec7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257138","created_at":"2021-01-18T10:36:04.617Z","updated_at":"2024-07-02T16:35:05.273Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia","source_id_and_acronym":"NCT02257138","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jakafi (ruxolitinib) • decitabine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 03/19/2021","primary_completion_date":" 03/19/2021","study_txt":" Completion: 03/19/2021","study_completion_date":" 03/19/2021","last_update_posted":"2024-05-08"},{"id":"3256127a-0abe-4b2e-b192-b4bbda0ec654","acronym":"","url":"https://clinicaltrials.gov/study/NCT01594723","created_at":"2021-01-18T06:48:50.034Z","updated_at":"2024-07-02T16:35:13.492Z","phase":"Phase 2","brief_title":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT01594723","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/22/2012","start_date":" 05/22/2012","primary_txt":" Primary completion: 03/20/2015","primary_completion_date":" 03/20/2015","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-21"},{"id":"90110e24-bfa4-4db8-9648-21c39c5dba73","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644211","created_at":"2021-01-19T20:39:16.893Z","updated_at":"2024-07-02T16:35:15.610Z","phase":"Phase 2","brief_title":"Ruxolitinib in Thrombocythemia and Polycythemia Vera","source_id_and_acronym":"NCT04644211","lead_sponsor":"Massachusetts General Hospital","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-08"},{"id":"9ea4e22c-7e50-4995-ab97-e08e5092ac72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03913026","created_at":"2021-01-18T19:15:26.504Z","updated_at":"2024-07-02T16:35:19.117Z","phase":"Phase 2","brief_title":"UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia","source_id_and_acronym":"NCT03913026","lead_sponsor":"Ciusss de L'Est de l'Île de Montréal","biomarkers":" TP53 • FLT3 • JAK2 • HLA-DRB1 • CD34","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation","tags":["TP53 • FLT3 • JAK2 • HLA-DRB1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zemcelpro (dorocubicel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-02-16"},{"id":"69a88472-75f1-4a2a-90e1-8b0bf04a99cd","acronym":"AALL1521","url":"https://clinicaltrials.gov/study/NCT02723994","created_at":"2021-01-18T13:19:54.627Z","updated_at":"2024-07-02T16:35:23.552Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02723994 - AALL1521","lead_sponsor":"Incyte Corporation","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion","tags":["JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-12"},{"id":"434adfdd-8113-4766-9f0b-9b5c20203527","acronym":"","url":"https://clinicaltrials.gov/study/NCT03571321","created_at":"2021-01-18T17:34:27.181Z","updated_at":"2024-07-02T16:35:27.762Z","phase":"Phase 1","brief_title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03571321","lead_sponsor":"University of Chicago","biomarkers":" JAK2 • CRLF2 • IL7R • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion","tags":["JAK2 • CRLF2 • IL7R • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/05/2027","study_completion_date":" 09/05/2027","last_update_posted":"2023-11-29"},{"id":"efbf6108-cc54-4f0c-937b-4e1967104f96","acronym":"","url":"https://clinicaltrials.gov/study/NCT01895842","created_at":"2021-01-18T08:30:36.207Z","updated_at":"2024-07-02T16:35:27.732Z","phase":"Phase 1","brief_title":"Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT01895842","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2 • NFKB1","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 04/02/2019","primary_completion_date":" 04/02/2019","study_txt":" Completion: 04/02/2019","study_completion_date":" 04/02/2019","last_update_posted":"2023-11-29"},{"id":"26110bab-e520-4fd5-a132-37b6e59b26a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03801434","created_at":"2021-01-18T18:47:30.564Z","updated_at":"2024-07-02T16:35:30.623Z","phase":"Phase 2","brief_title":"Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","source_id_and_acronym":"NCT03801434","lead_sponsor":"William Shomali","biomarkers":" JAK2 • ETV6 • PCM1","pipe":" | ","alterations":" JAK2 mutation • JAK2 rearrangement","tags":["JAK2 • ETV6 • PCM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation • JAK2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/15/2019","start_date":" 11/15/2019","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-11-02"},{"id":"ad6effdc-77e6-48b7-93c9-786714c4d278","acronym":"EXCEED ET","url":"https://clinicaltrials.gov/study/NCT05482971","created_at":"2023-07-03T18:10:07.965Z","updated_at":"2024-07-02T16:35:34.897Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","source_id_and_acronym":"NCT05482971 - EXCEED ET","lead_sponsor":"PharmaEssentia","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 09/29/2022","start_date":" 09/29/2022","primary_txt":" Primary completion: 07/29/2024","primary_completion_date":" 07/29/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-03"},{"id":"15695fd3-66d3-4fb9-b21e-0b44fa5313eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04217993","created_at":"2021-01-18T20:32:06.057Z","updated_at":"2024-07-02T16:35:49.973Z","phase":"Phase 2","brief_title":"Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis","source_id_and_acronym":"NCT04217993","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 08/03/2022","primary_completion_date":" 08/03/2022","study_txt":" Completion: 08/03/2022","study_completion_date":" 08/03/2022","last_update_posted":"2023-04-20"},{"id":"941b1153-fb94-4360-9c39-d0685da9af97","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393509","created_at":"2021-01-18T05:43:22.326Z","updated_at":"2024-07-02T16:35:52.184Z","phase":"Phase 1","brief_title":"The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT01393509","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" JAK2 • CD4","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zelavespib intravenous (PU-H71 IV)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 07/06/2011","start_date":" 07/06/2011","primary_txt":" Primary completion: 03/23/2023","primary_completion_date":" 03/23/2023","study_txt":" Completion: 03/23/2023","study_completion_date":" 03/23/2023","last_update_posted":"2023-03-28"},{"id":"5f2786e3-cd23-4edd-a1bd-514ed1a1188c","acronym":"REALISE","url":"https://clinicaltrials.gov/study/NCT02966353","created_at":"2021-01-18T14:34:48.777Z","updated_at":"2024-07-02T16:36:45.464Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.","source_id_and_acronym":"NCT02966353 - REALISE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 03/31/2017","start_date":" 03/31/2017","primary_txt":" Primary completion: 07/24/2018","primary_completion_date":" 07/24/2018","study_txt":" Completion: 02/15/2019","study_completion_date":" 02/15/2019","last_update_posted":"2020-04-30"},{"id":"81f945cb-5dfa-4632-b320-22d02b5e3f53","acronym":"","url":"https://clinicaltrials.gov/study/NCT00606307","created_at":"2021-01-18T02:15:01.813Z","updated_at":"2024-07-02T16:36:52.963Z","phase":"Phase 2a","brief_title":"Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases","source_id_and_acronym":"NCT00606307","lead_sponsor":"Italfarmaco","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Duvyzat (givinostat)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 12/01/2007","start_date":" 12/01/2007","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 12/01/2008","study_completion_date":" 12/01/2008","last_update_posted":"2019-12-03"},{"id":"fca6fe2f-706b-4bc8-9d90-aea678116342","acronym":"SAKK 33/14","url":"https://clinicaltrials.gov/study/NCT02311569","created_at":"2021-01-18T10:56:39.363Z","updated_at":"2024-07-02T16:36:59.538Z","phase":"Phase 2","brief_title":"Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation","source_id_and_acronym":"NCT02311569 - SAKK 33/14","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mirabegron"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2019-05-15"},{"id":"c6624709-4629-4e7f-bcde-f0f06e3192bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493414","created_at":"2021-01-18T06:15:17.831Z","updated_at":"2024-07-02T16:37:00.162Z","phase":"Phase 3","brief_title":"INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.","source_id_and_acronym":"NCT01493414","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 2233","initiation":"Initiation: 08/16/2011","start_date":" 08/16/2011","primary_txt":" Primary completion: 01/26/2017","primary_completion_date":" 01/26/2017","study_txt":" Completion: 01/26/2017","study_completion_date":" 01/26/2017","last_update_posted":"2019-04-26"},{"id":"0659227f-d0fb-4536-839e-0b6d4a52a25d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01134120","created_at":"2021-01-18T04:30:30.495Z","updated_at":"2024-07-02T16:37:11.464Z","phase":"Phase 1","brief_title":"A Study in Myeloproliferative Disorders","source_id_and_acronym":"NCT01134120","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 02/22/2018","study_completion_date":" 02/22/2018","last_update_posted":"2018-04-17"},{"id":"2fe5c637-4e3d-4c63-9f81-6c13c0cc1278","acronym":"","url":"https://clinicaltrials.gov/study/NCT00910728","created_at":"2021-01-18T03:31:08.657Z","updated_at":"2024-07-02T16:37:23.143Z","phase":"Phase 1","brief_title":"Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases","source_id_and_acronym":"NCT00910728","lead_sponsor":"AstraZeneca","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD1480"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2017-04-24"},{"id":"8207a8b7-15c7-474d-91a3-dde6c57d5b0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02087059","created_at":"2021-01-18T09:37:17.268Z","updated_at":"2024-07-02T16:37:30.780Z","phase":"Phase 3","brief_title":"A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis","source_id_and_acronym":"NCT02087059","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2016-07-11"}]